Results 1 to 10 of about 4,709,369 (278)
Canadian Medical Association Journal, 2021 Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy.
V. Makker +6 more
semanticscholar +9 more sources
The Lancet, 2022 Endometrial cancer is the most common gynaecological cancer in high income countries and its incidence is rising globally. Although an ageing population and fewer benign hysterectomies have contributed to this trend, the growing prevalence of obesity is the major underlying cause.
E. J. Crosbie +5 more
semanticscholar +6 more sources
Expert consensus on genetic counseling in gynecological oncology (2023 edition) [PDF]
Zhongguo aizheng zazhi, 2023 With the increasing applications of high-throughput genome sequencing technology, there is a growing recognition of the important roles of genetic factors in the occurrence and development of gynecological tumors.
doaj +1 more source
Best Practice & Research Clinical Obstetrics & Gynaecology, 2012 Endometrial carcinoma is the most common gynaecological malignancy in the Western world. The standard management of endometrial carcinoma is total hysterectomy and bilateral salpingo-oophorectomy with or without pelvic and para-aortic lymph-node dissection.
Vivek, Arora, Michael A, Quinn
+10 more sources
Expression of STAT3 in endometrial carcinoma and its clinicopathological significance [PDF]
Jichu yixue yu linchuang, 2023 Objective To investigate the expression of signal transducer and activator of transcription 3 (STAT3) in endometrial cancer tissues, and to analyze its relationship with common pathological parameters.
SUN Xinzhao, LUO Yanlu, FAN Jiangtao, ZHONG Xueyan
doaj +1 more source
Biomolecules & Biomedicine, 2022 Endometrial cancer is the second gynecological cancer with the highest global incidence. Among many associated risk factors, metabolic syndrome is an important and preventable one.
Alejandra Rocío Pérez-Martín +8 more
doaj +1 more source
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
New England Journal of Medicine, 2023 BACKGROUND Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
M. Mirza +30 more
semanticscholar +1 more source
Frontiers in Genetics, 2022 Background: Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13–17% of ovarian cancers are due to heritable mutations in BRCA1 and BRCA2.
Dolores Gallardo-Rincón +21 more
doaj +1 more source
FIGO staging of endometrial cancer: 2023
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023 Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009.
Jonathan S Berek +8 more
semanticscholar +1 more source
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
New England Journal of Medicine, 2023 BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander +26 more
semanticscholar +1 more source